Tyrosine kinase inhibitors such as erlotinib are commonly used as a therapeutic agent
against cancer due to its relatively low side-effect profile and, at times, greater efficacy …

In non-small-cell lung cancer (NSCLC) patients, the activation of alternative pathways
contributes to the limited efficacy of the epidermal growth factor receptor (EGFR) tyrosine …

EGFR-TKI targeted therapy is one of the most effective treatments for lung cancer patients
harboring EGFR activating mutations. However, inhibition response is easily attenuated by …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR–TKIs) have become a
standard therapy for non-small cell lung cancer (NSCLC) patients with sensitive mutations …

Drug resistance of non-small cell lung cancer (NSCLC) is highly correlated to the mutation of
the epidermal growth factor receptor (EGFR). Although EGFR tyrosine kinase inhibitors …

Background: Targeted therapy for lung cancer with epidermal growth factor receptor (EGFR)
mutations with tyrosine kinase inhibitors (TKIs) represents one of the major breakthroughs in …

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations are responsive to EGFR-tyrosine kinase inhibitor (EGFR-TKI). However, NSCLC …

Background The receptor tyrosine kinase (RTK) EGFR is overexpressed and mutated in
NSCLC. These mutations can be targeted by RTK inhibitors (TKIs) such as erlotinib …

Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI), used for treating patients with advanced non-small-cell lung …

Abstract epidermal growth factor receptor (EGFR) somatic mutations are found in the
majority of non‑small‑cell lung cancers (NSCLCs) and patients with NSCLC who harbor …